Angle Is Ready To Capitalize On Promise Of Capture Cell Technology
Angle PLC has published half year interim results which indicate it will capitalize on a new liquid biopsy market.
You may also be interested in...
The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.
With approvals looming over the next few months, Angle spoke to Medtech Insight to probe deeper about its presentation at the 2021 Jefferies Healthcare Conference.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.